GlobeNewswire: TESARO, Inc. Contains the last 10 of 238 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:04:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/03/05/1747932/0/en/TESARO-Announces-Data-Presentations-at-the-2019-SGO-Annual-Meeting-on-Women-s-Cancer.html?f=22&fvtc=4&fvtv=15863TESARO Announces Data Presentations at the 2019 SGO Annual Meeting on Women’s Cancer2019-03-05T12:30:00Z<![CDATA[WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- TESARO, an oncology-focused business within GSK, today announced that data for dostarlimab (anti-PD-1 antibody, formerly TSR-042) and Zejula® (niraparib) will be presented at the 2019 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer being held March 16-19 in Honolulu, Hawaii.]]>https://www.globenewswire.com/news-release/2019/02/26/1742293/0/en/Actor-Scott-Foley-and-TESARO-Team-Up-to-Empower-Ovarian-Cancer-Care-Partners-Through-New-Phase-of-Not-on-My-Watch-Movement.html?f=22&fvtc=4&fvtv=15863Actor Scott Foley and TESARO Team Up to Empower Ovarian Cancer Care Partners Through New Phase of Not on My Watch Movement2019-02-26T12:30:00Z<![CDATA[In a New Public Service Announcement, Foley Reveals for the First Time his Personal Story of Caring for his Mother Following Ovarian Cancer Recurrence In a New Public Service Announcement, Foley Reveals for the First Time his Personal Story of Caring for his Mother Following Ovarian Cancer Recurrence]]>https://www.globenewswire.com/news-release/2019/01/24/1704828/0/en/TESARO-Inc-Provides-Notice-of-Fundamental-Change-Conversion-Rate-Adjustment-pursuant-to-Make-Whole-Adjustment-Event-and-Supplemental-Indenture.html?f=22&fvtc=4&fvtv=15863TESARO, Inc. Provides Notice of Fundamental Change, Conversion Rate Adjustment pursuant to Make-Whole Adjustment Event and Supplemental Indenture2019-01-24T13:00:00Z<![CDATA[WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc. (the “Company” or “TESARO”), an oncology-focused biopharmaceutical company, today announced that pursuant to the terms of the Indenture and the First Supplemental Indenture to the Indenture (collectively, the “Indenture”) governing the terms of its 3.00% Convertible Senior Notes due 2021 (the “Notes”), a Fundamental Change and a Make-Whole Adjustment Event, as such terms are defined in the Indenture, occurred as a result of completion of the offer (the “Offer”) and the merger (the “Merger”), respectively, contemplated by the Agreement and Plan of Merger, dated December 3, 2018 (the “Agreement”), by and between TESARO, GlaxoSmithKline plc and Adriatic Acquisition Corporation.]]>https://www.globenewswire.com/news-release/2018/12/04/1662088/0/en/TESARO-Inc-Gives-Notice-of-Anticipated-Make-Whole-Adjustment-Event-to-Holders-of-Its-Convertible-Senior-Notes.html?f=22&fvtc=4&fvtv=15863TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes2018-12-04T21:15:00Z<![CDATA[WALTHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that, pursuant to the terms of the indenture (the “Indenture”) governing the terms of its 3.00% Convertible Senior notes due 2021 (the “Notes”), it anticipates that a Make-Whole Adjustment Event, as such term is defined in the Indenture, will occur as a result of completion of the proposed transactions contemplated by the Agreement and Plan of Merger, dated December 3, 2018 (the “Agreement”), by and between TESARO, GlaxoSmithKline plc (“Parent”) and Adriatic Acquisition Corporation (“Purchaser”).]]>https://www.globenewswire.com/news-release/2018/12/03/1660671/0/en/GSK-reaches-agreement-to-acquire-TESARO-an-oncology-focused-biopharmaceutical-company.html?f=22&fvtc=4&fvtv=15863GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company2018-12-03T12:04:00Z<![CDATA[LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology.]]>https://www.globenewswire.com/news-release/2018/11/09/1649186/0/en/TESARO-Announces-Immuno-Oncology-Data-Presentations-at-SITC-2018-Annual-Meeting.html?f=22&fvtc=4&fvtv=15863TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting2018-11-09T20:41:00Z<![CDATA[WASHINGTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today presented initial data from the Phase 1 AMBER trial of TSR-022 (anti-TIM-3 antibody) in combination with TSR-042 (anti-PD-1 antibody) in patients who have progressed following anti-PD-1 therapy treatment, in an oral session during the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference in Washington, D.C. Additionally, Phase 1 GARNET data of TSR-042 in patients with previously treated recurrent/advanced non-small cell lung cancer (NSCLC) and Phase 1 monotherapy dose-escalation data for TSR-033 (anti-LAG-3 antibody) in a broad range of solid tumors were also highlighted in poster presentations.]]>https://www.globenewswire.com/news-release/2018/11/01/1641640/0/en/TESARO-Announces-Third-Quarter-2018-Operating-Results.html?f=22&fvtc=4&fvtv=15863TESARO Announces Third-Quarter 2018 Operating Results2018-11-01T20:05:00Z<![CDATA[WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today reported operating results for third-quarter 2018 and provided an update on the Company's commercial products and development programs.]]>https://www.globenewswire.com/news-release/2018/10/30/1639082/0/en/The-Foundation-for-Women-s-Cancer-and-TESARO-Partner-on-the-Race-to-End-Women-s-Cancer-for-3rd-Year.html?f=22&fvtc=4&fvtv=15863The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year2018-10-30T12:05:00Z<![CDATA[CHICAGO and WALTHAM, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), and TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the third year of their partnership supporting the annual National Race to End Women’s Cancer. The weekend-long event is the FWC’s pinnacle awareness and fundraising event, celebrating survivors, honoring loved ones, creating awareness and supporting women with gynecologic cancers. TESARO is the Presenting Break-Through Sponsor of the 9th annual event, which features a 5K run and 1-mile walk on Sunday, November 4, at Freedom Plaza in Washington, D.C.]]>https://www.globenewswire.com/news-release/2018/10/29/1638216/0/en/TESARO-Announces-Achievement-of-ZEJULA-Prostate-Cancer-Development-Milestones-by-Janssen.html?f=22&fvtc=4&fvtv=15863TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen2018-10-29T12:00:00Z<![CDATA[WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger an $18 million payment from Janssen Biotech Inc. (Janssen). The milestones are related to Janssen’s ongoing GALAHAD trial, which is assessing niraparib monotherapy for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair anomalies. Data from the trial are anticipated to support global regulatory filings in 2019.]]>https://www.globenewswire.com/news-release/2018/10/24/1626204/0/en/TESARO-and-Actress-Cobie-Smulders-Launch-Not-on-My-Watch-a-National-Movement-to-Empower-the-Ovarian-Cancer-Community.html?f=22&fvtc=4&fvtv=15863TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community2018-10-24T12:00:00Z<![CDATA[Not on My Watch Aims to Shine a Light on the Importance of an Informed, Proactive Approach to Treatment]]>